The objective of this study was to assess the achievement of pharmacokinetic/pharmacodynamic (PK/PD) targets of meropenem (MEM) in critically-ill patients with bloodstream infections (BSI) due to Klebsiella pneumoniae-carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) with MEM minimum inhibitory concentrations (MICs) ≥16 mg/L. Nineteen ...

2025年3月11日 · This approach allowed correlation of resistance changes with specific mutations. Most KPC-2 cluster variants showed lower MICs for piperacillin, piperacillin-tazobactam, cefazolin, cefuroxime, imipenem, and meropenem (MEM) compared to the KPC-2 reference strain . Only a few variants, such as KPC-6 and KPC-30, exhibited increased MICs for ...

Enrolled patients had K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) infections (59.5% of which were ceftazidime/avibactam resistant). Patients who received ≥72 h of meropenem/vaborbactam therapy (with or without other antimicrobials) in a compassionate-use setting were included.

2023年6月1日 · FOS plus MEM may be an option for KPC-variant infections at low risk of mortality. Little is known regarding outcomes and optimal therapeutic regimens of infections caused by Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae (KPC-Kp) resistant to ceftazidime/avibactam (CZA) and susceptible to meropenem (MEM).

2025年2月1日 · In the present study, we identified and characterised a novel KPC variant in ATM-AVI-resistant K. pneumoniae, which featured a serine‑to-proline substitution at Ambler position 109 of KPC-2. We cloned bla KPC-2 (S109P) into E. coli DH5α and found that this mutation increased susceptibility to ATM and CAZ, but significantly reduced ...

The sensitivities and specificities of the ETP, IPM, and MEM disc diffusion method for the detection of class A carbapenemase among Enterobacteriaceae were estimated using the combination of the MHT and the PCR for KPC as the gold standard.

2024年8月27日 · Klebsiella pneumoniae strains that produce Klebsiella pneumoniae Carbapenemase (KPC) variants displaying resistance to ceftazidime-avibactam (CZA) often remain susceptible to meropenem (MEM), suggesting a potential therapeutic use of this carbapenem antibiotic.

2023年4月23日 · Although susceptible to MEM in vitro, the possibility of developing MEM resistance overtime is a concern. We describe the clinical characteristics of patients with colonization/infection due to KPC variants with a focus on the in vitro activity of fosfomycin (FOS)-containing combinations.

2023年1月23日 · The purpose of this study was to select for MEM-VAB resistance using a collection of eight KPC-producing Klebsiella pneumoniae clinical isolates, including three that produce KPC variants conferring ceftazidime-avibactam (CAZ-AVI) resistance, and subsequently decipher the corresponding resistance mechanisms.

2024年9月1日 · Through a series of biochemical tests, this study identified a compound known as AN2718 which can act as an effective inhibitor of KPC-2, the enzyme produced by carbapenem-resistant strains which is responsible for causing carbapenem resistance, thereby restoring the antimicrobial activity of MEM against the resistant strains.